Summary by Moomoo AI
bluebird bio, Inc. has announced a significant change in its executive team with the departure of Christopher Krawtschuk as Chief Financial Officer and principal accounting officer, effective June 10, 2024. The company clarified that Krawtschuk's departure is not due to any disagreements on accounting policies or business strategy. Concurrently, the Board of Directors has appointed O. James Sterling as the new Chief Financial Officer, with his role also commencing on June 10, 2024. Sterling brings experience from his previous role as CFO of Renalytix plc and has held positions at Renwick Capital LLC and investment banks Brock Capital Group LLC and Aleutian Capital Group. His appointment comes with a comprehensive compensation package, including a $500,000 annual salary, a $100,000 sign-on bonus, a 45% target annual bonus, and an initial equity grant. The company has detailed the terms of Sterling's employment and severance provisions, as well as the severance arrangements for Krawtschuk, in line with his existing employment agreement.
